Lutetium Lu 177 Treatment for Prostate Cancer

This trial tests a treatment called lutetium Lu 177, a type of radiopharmaceutical therapy, for prostate cancer that has spread and no longer responds to standard hormone therapy. Researchers aim to determine if a blood test measuring circulating tumor DNA (ctDNA) can guide decisions to stop this treatment early if it proves ineffective. Patients with low ctDNA levels will continue the treatment, while those with high levels might switch to a different therapy. Men with prostate cancer that has spread to areas like bones and who have tried at least one unsuccessful hormone therapy may be suitable candidates. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

In a previous study, patients treated with lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) experienced common side effects such as tiredness, dry mouth, nausea, low red blood cell count (anemia), loss of appetite, and constipation. This treatment can also damage genetic information and potentially cause cancer, so careful use is essential.

Research has shown that docetaxel, another treatment option, is generally considered safe but can have serious side effects. In one study, 34% of patients receiving docetaxel required hospitalization, and about 16.5% experienced febrile neutropenia, a condition involving a low white blood cell count and fever that requires immediate medical care.

Researchers are excited about Lutetium Lu 177 Vipivotide Tetraxetan because it offers a targeted approach for treating prostate cancer. Unlike traditional chemotherapy, which affects both cancerous and healthy cells, this treatment uses a radioactive compound that specifically targets and binds to PSMA, a protein commonly found on prostate cancer cells, delivering radiation directly to the tumor. This targeted mechanism could potentially minimize side effects and improve treatment effectiveness. Additionally, the use of ctDNA testing helps tailor the treatment to each patient's response, potentially leading to more personalized and effective care.

Research has shown that lutetium Lu 177 vipivotide tetraxetan, a treatment in this trial, effectively treats advanced prostate cancer that no longer responds to hormone therapy. In one study, 68.9% of patients experienced a significant drop in PSA levels (a protein made by prostate cells) by 10% or more, and 55.6% saw a reduction of 50% or more. This treatment also helped patients live longer without their cancer worsening. Meanwhile, docetaxel, another treatment option in this trial, improved survival rates and reduced deaths specifically from prostate cancer by 70%. Both treatments have strong potential to help manage advanced prostate cancer.⁶⁷⁸⁹¹⁰